Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01455636
Other study ID # 1000014576
Secondary ID
Status Completed
Phase Phase 3
First received October 16, 2011
Last updated June 30, 2015
Start date June 2010
Est. completion date April 2012

Study information

Verified date June 2015
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

Low birth weight (LBW) infants are particularly vulnerable to frequent infections and consequent morbidity resulting in sub-optimal breastfeeding, limited ingestion of complementary foods and ultimately micronutrient deficiencies that result in post-natal linear growth faltering. The objective of this study is to facilitate improved feeding practices through the early reduction of infections using the innovative tools of water-based hand sanitizer (beginning at birth) and an improved micronutrient powder (I-MNP) (beginning at 6 months of age). A community-based cluster randomized controlled trial will be carried out in Bangladesh using a 2x2 factorial design. LBW infants (n=480) will be recruited at birth and allocated to either HS or No HS from 0 to 6 months. From 6 to 12 months, half of the children in each group will be randomized to receive I-MNP. All groups will receive nutrition and hygiene education from birth to 12 months. Recumbent length is the primary outcome; morbidity, dietary intake and hemoglobin will be assessed as secondary outcomes. By working with BRAC, the largest implementation agency in Bangladesh, there is the opportunity to translate the results directly and quickly into child health programs in Bangladesh.


Description:

General Objective To explore the relative effect of hand sanitizer and home fortification with an improved MNP (plus nutrition education) to prevent infections, improve feeding and ultimately to improve growth among LBW infants in Bangladesh.

Specific Objectives Although the applicants clearly understand that the primary purpose of the Alive and Thrive RFP is to improve infant feeding, we believe that by preventing infections, feeding will improve and growth will accelerate. Thus our primary objective is to determine the relative effect of intervention packages to improve feeding and thus prevent or reverse linear growth faltering and reduce rates of stunting among LBW infants (Ha: Combination of all three interventions will improve feeding and prevent or reverse linear growth faltering and reduce rates of stunting)

Secondary objectives (i) Investigate the effect of intervention packages on rates of diarrhea and acute respiratory tract infection (ARI).

(Ha: Combination of all three interventions will reduce on rates of diarrhea and acute respiratory tract infection) (ii) Explore the effect of the intervention packages on energy and nutrient intakes of infants and their feeding behaviors.

(Ha: Combination of all three interventions will increase energy and nutrient intakes of infants and improve the feeding behaviors) (iii) Determine the impact of the improved MNP on iron status (hemoglobin level in blood) in a subgroup.

(Ha: The group receiving the improved MNP will have increased hemoglobin level in blood and reduced rates of anemia)


Recruitment information / eligibility

Status Completed
Enrollment 467
Est. completion date April 2012
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- infants born as singletons and full term (mothers will be identified at ~8 months or >37 weeks gestation to avoid including premature babies who are at high risk of neonatal mortality).

- must have a birth weight =1800g and <2500g.

- Families involved in the study must be planning to remain in the study community for the next 12 months

- written consent must be received from an authorized guardian.

- all pregnant women will be identified and visited during their 8th month of pregnancy. A local informant will be identified for birth notification, who will inform the CHW (with a cell phone) when a child is born. All newborns will be screened and those who meet the inclusion criteria will be enrolled.

Exclusion Criteria:

- newborns with severe illnesses or congenital abnormalities /severe malformations that affect feeding will be excluded from the study.

- infants whose mothers did not survive during childbirth will be excluded.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Hand Sanitizer
The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
Dietary Supplement:
Improved Micronutrient Powder
A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
Other:
No hand sanitizer
All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene. No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed
Dietary Supplement:
No Micronutrient Powder
I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.

Locations

Country Name City State
Bangladesh Research and Evaluation Division, BRAC Dhaka
Canada The Hospital for Sick Children Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
The Hospital for Sick Children

Countries where clinical trial is conducted

Bangladesh,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Anthropometry - Recumbent Length Recumbent length will be measured to 0.01cm on a locally constructed wooden stadiometer. Anthropometric data will be converted to Z-scores using the WHO growth standards. Change from baseline in length over 12 months No
Primary Anthropometry - Weight weight using an infant balance with 15 g precision (SECA Model 345) calibrated on a regular, scheduled basis. Anthropometric data will be converted to Z-scores using the WHO growth standards. Change from baseline in weight over 12 months No
Secondary Infectious Morbidity Diarrhea will be defined as >3 loose stools in a 24-h period or >1 loose stool containing blood. Mothers are expected to use ORS and zinc tablets for all diarrhea episodes (provided free to study subjects irrespective of study group). Acute Respiratory Infections (ARI) will be diagnosed according to World Health Organization Criteria Information on the occurrence, type and severity of diarrhea and ARI and health seeking be collected weekly. Weekly for 52 weeks No
Secondary Infant and young child feeding Information on age-specific feeding practices will be obtained monthly by trained nutritionists using standardized infant and young child feeding indicators. Monthly for 12 months No
Secondary Blood collection and Hemoglobin (Hb) measurement A standardized finger-prick technique will be used to collect blood from the infants from a subsample of Groups 2 and 4 (at 6 and 12 months). Hb will be measured using a portable Hemocue (Hemocue Inc.). 6 and 12 months post randomization No
Secondary Socioeconomic status (SES) and demographic information Household SES will be assessed by a pre-coded structured interview designed to obtain information on the household demographic structure, parental education, employment, material possessions and by inspection of housing quality. Baseline No
Secondary Household Food Security Information on household food security will be collected using standardized questionnaires used in the same population. Baseline No
See also
  Status Clinical Trial Phase
Completed NCT02379728 - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth N/A
Withdrawn NCT01335919 - Neonatal Non-Invasive Hemoglobin Determination N/A
Completed NCT00114543 - Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Phase 3
Completed NCT00011362 - Dexamethasone Therapy in VLBW Infants at Risk of CLD Phase 3
Active, not recruiting NCT02944682 - Household Air Pollution and Health: A Multi-country LPG Intervention Trial N/A
Recruiting NCT00005889 - Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion N/A
Completed NCT01203423 - Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study
Completed NCT01223287 - Physiologic Definition of Bronchopulmonary Dysplasia N/A
Not yet recruiting NCT04866277 - Experimental Study to Reduce Low Birthweight N/A
Completed NCT00593801 - Erythropoietin Treatment in Extremely Low Birth Weight Infants N/A
Completed NCT00109525 - Early Diagnosis of Candidiasis in Premature Infants
Completed NCT01223261 - Observational Study of Surgical Treatment of Necrotizing Enterocolotis
Completed NCT00067613 - Benchmarking Initiative to Reduce Bronchopulmonary Dysplasia N/A
Completed NCT05358509 - Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial Phase 4
Completed NCT02377817 - Halifax PrenaBelt Trial N/A
Completed NCT00349726 - Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants Phase 2
Completed NCT01222364 - Delayed Cord Clamping in VLBW Infants Phase 1/Phase 2
Completed NCT01203449 - Development of Standards for the New Ballard Maturation Score N/A
Completed NCT00874393 - Early Blood Pressure Management in Extremely Premature Infants Phase 1
Completed NCT00873847 - Cerebral Function Monitoring in Premature Infants N/A